Nyxoah SA
NYXH
Positions held
Your positionsNYXH isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $137.48M | Enterprise value | $97.30M | Trailing P/E | — | Forward P/E | -1.64 |
| PEG | — | Price / book | 1.43 | Beta | 1.00 | Dividend yield | 0.00% |
| Revenue growth | 4.7% | Earnings growth | — | Gross margin | 60.2% | Operating margin | -2.7% |
| Profit margin | 0.0% | ROE | -122.7% | ROA | -36.9% | Debt / equity | 0.72 |
| Current ratio | 2.38 | Free cash flow | -$46.06M | Analyst recommendation | none | Mean target | $4.20 |
| 52w high | $6.88 | 52w low | $1.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $7.7M | $6.4M | $5.6M | $2.0M | $1.3M |
| Op margin | -267.7% | -321.8% | -323.5% | -1226.9% | -1481.3% |
| Net income | -$33.0M | -$15.9M | -$23.5M | -$23.6M | -$20.6M |
| Gross margin | 59.7% | 57.1% | 64.2% | 60.5% | 63.4% |
| Gross profit | $4.6M | $3.6M | $3.6M | $1.2M | $0.8M |
| Operating income | -$20.5M | -$20.5M | -$18.3M | -$24.2M | -$19.9M |
- Revenue +20% vs prior quarter ($7.7M vs $6.4M).
- Gross margin 59.7% (was 57.1% prior quarter).
- Operating margin expanded to -267.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $10.0M | $4.5M | $4.3M | $3.1M |
| Op margin | -827.8% | -1300.8% | -1037.3% | -1053.8% |
| Net income | -$90.1M | -$59.2M | -$43.2M | -$31.2M |
| Gross margin | 63.1% | 65.7% | 61.9% | 62.7% |
| Gross profit | $6.3M | $3.0M | $2.7M | $1.9M |
| Operating income | -$82.9M | -$58.8M | -$45.1M | -$32.5M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?
2026-09-28 · Nyxoah Names Liam Kelly as Chief Executive
2026-09-28 · Nyxoah Appoints Liam Kelly as Chief Executive Officer
2026-09-23 · CVRx names John Landry as CFO
2026-09-21 · Nyxoah Names Loic Moreau Interim CFO as John Landry Steps Down
2026-09-21 · CVRx Names New Chief Financial Officer
2026-09-21 · CVRx Appoints John Landry as Chief Financial Officer
2026-09-21 · Nyxoah Announces Chief Financial Officer Transition
2026-09-10 · Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?
2026-09-08 · Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
2026-09-08 · Nyxoah Implants First Patient in Sleep Apnea Device Study
2026-09-07 · Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Price (daily)
Full chart · RSI · MACD · patterns